|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Wireless capsule endoscopy in the investigation of patients with chronic renal failure and obscure gastrointestinal bleeding (preliminary data)显示文摘瞄准:在小肠(SB ) 的察觉调查无线的囊内视镜检查法(WCE ) 的角色在有长期的肾衰竭(CRF ) 并且阴暗流血的病人的病理。方法:有阴暗流血的连续 CRF 病人有希望地被学习。有正常肾的功能并且阴暗流血的病人,与 WCE 在一样的时期期间调查了,被用于结果的解释。结果:十七个 CRF 病人(11 公开, 6 玄术流血) 并且 51 个病人(33 公开, 18 玄术流血) 与正常,肾的功能在这研究被注册。积极 SB 调查结果在 70.6% CRF 病人被检测(P <
0.05 ) 。SB angiodysplasia 在 47% CRF 病人被识别。Univariate 逻辑回归为 angiodysplasia 作为一个重要预兆的因素揭示了 CRF (P <
0.05 ) 。治疗学的措施与积极调查结果在 66% 病人被承担。结论:根据我们的初步的结果, SB angiodysplasia 与阴暗流血在 CRF 病人之中在增加的流行被发现。WCE 在胃肠的病理的诊断并且在计划适当治疗学的干预是有用的并且因此,应该在这组病人的病情的检查被包括。 | Stephanos Karagiannis Spyros Goulas Georgios Kosmadakis Petros Galanis Dimitrios Arvanitis John Boletis Evangelos Georgiou Christos Mavrogiannis | 2006 | World Journal of Gastroenterology2006，12，32： | 8 |
| 2 | Renal transplantation with expanded criteria donors: Which is the optimal immunosuppression?显示文摘The growing gap between demand and supply for kidney transplants has led to renewed interest in the use of expanded criteria donor(ECD) kidneys in an effort to increase the donor pool. Although most studies of ECD kidney transplantation confirm lowerallograft survival rates and, generally, worse outcomes than standard criteria donor kidneys, recipients of ECD kidneys generally have improved survival compared with wait-listed dialysis patients, thus encouraging the pursuit of this type of kidney transplantation. The relative benefits of transplantation using kidneys from ECDs are dependent on patient characteristics and the waiting time on dialysis. Because of the increased risk of poor graft function, calcineurin inhibitor(CNI)-induced nephrotoxicity, increased incidence of infections, cardiovascular risk, and malignancies, elderly recipients of an ECD kidney transplant are a special population that requires a tailored immunosuppressive regimen. Recipients of ECD kidneys often are excluded from transplant trials and, therefore, the optimal induction and maintenance immunosuppressive regimen for them is not known. Approaches are largely center specific and based upon expert opinion. Some data suggest that antithymocyte globulin might be the preferred induction agent for elderly recipients of ECD kidneys. Maintenance regimens that spare CNIs have been advocated, especially for older recipients of ECD kidneys. CNI-free regimens are not universally accepted due to occasionally high rejection rates. However, reduced CNI exposure and CNI-free regimens based on mammalian target of rapamycin inhibitors have shown acceptable outcomes in appropriately selected ECD transplant recipients. | Vassilis Filiopoulos John N Boletis | 2016 | World Journal of Transplantation2016，6，1： | 3 |
| 3 | Hepatitis C in hemodialysis patients显示文摘Despite reduction of hepatitis C prevalence after recognition of the virus and testing of blood products, hemodialysis(HD) patients still comprise a high risk group. The natural history of hepatitis C virus(HCV) infection in dialysis is not fully understood while the clinical outcome differs from that of the general population. HD patients show a milder liver disease with lower aminotransferase and viral levels depicted bymilder histological features on liver biopsy. Furthermore, the 'silent' clinical course is consistent with a slower disease progression and a lower frequency of cirrhosis and hepatocellular carcinoma. Potential explanations for the 'beneficial' impact of uremia and hemodialysis on chronic HCV infection are impaired immunosurveillance leading to a less aggressive host response to the virus and intradialytic release of 'hepatoprotective' cytokines such as interferon(IFN)-α and hepatocyte growth factor. However, chronic hepatitis C is associated with a higher liver disease related cardiovascular and allcause mortality of HD patients. Therapy is indicated in selected patients groups including younger patients with low comorbidity burden and especially renal transplant candidates, preferably after performance of a liver biopsy. According to current recommendations, choice of treatment is IFN or pegylated interferon with a reported sustained viral response at 30%-40% and a withdrawal rate ranging from 17% to 30%. New data regarding combination therapy with low doses of ribavirin which provide higher standard variable rates and good safety results, offer another therapeutic option. The new protease inhibitors may be the future for HCV infected HD patients, though data are still lacking. | Smaragdi Marinaki John N Boletis Stratigoula Sakellariou Ioanna K Delladetsima | 2015 | World Journal of Hepatology2015，7，3： | 2 |
| 4 | Excellent long term patient and renal allograft survival after ABO-incompatible kidney transplantation:Experience of one center显示文摘AIM: To investigate the long-term results of ABOincompatible(ABOi) kidney transplantation in a single center in Greece.METHODS: Thirty consecutive ABOi kidney transplantations were performed from June 2005 to December 2013. All patients received rituximab one month prior to transplantation. Immunoadsorption therapy was performed for the removal of anti-A/B Ig G antibodies until the titer was ≤ 1:16. Additional apheresis sessions were performed post-operatively. Intravenous immunoglobulin and oral immunosuppression consisting of tacrolimus(TAC) in combination with either everolimus or mycophenolate acid was administered. We compared the long term results of our ABOi group to those of a matched group of 30 ABO compatible(ABOc) living kidney recipients with similar baseline characteristics. The ABOc recipients received an immunosuppressive regimen consisting of TAC and mycophenolate acid. All patients in both groups received induction therapy with Basiliximab or Daclizumab, whereas corticosteroids were instituted on the day of surgery. During the followup period, indication biopsies were performed and interpreted by an experienced nephropathologist. The parameters we analyzed included the following: Donor/recipient age, gender, blood type, human leukocyte antigen mismatches, panel reactive antibodies, primary cause of renal failure, mean time on dialysis, immunosuppressive regimen, patient survival, graft outcome, incidence of rejections, surgical and infectious complications.RESULTS: The mean follow-up period was 6 years(range 1 to 9 years). A mean of 5.0 ± 3.0(range 0-14) pre-transplant immunoadsorptions were required in order to reach the target titer. Patient survival in ABOi group in comparison to ABOc group at 1, 3, 5 and 8 years did not differ significantly(100% vs 100%, 96% vs 100%, 92% vs 100% and 92% vs 100%, P = ns). Additionally, graft survival was similar in the two groups at the same time points(100% vs 100%, 96% vs 96%, 92% vs 96% and 81% vs 92%, P = ns). The mean serum creatinine and the estimated glomerular filtration rate by the modification of diet in renal disease formula at 1, 3, 5 and 8 years did not differ significantly between ABOi and ABOc group. None of the patients in the ABOi group developed acute or chronic antibodymediated rejection evidenced by histological signs. Four patients(13.3%) in the ABOi group and 3(10%) in the ABOc group experienced acute cellular rejection, which was treated successfully in all cases. Bacterial and viral infections were also similar between the two groups.CONCLUSION: ABOi kidney transplantation is a safe and effective alternative that enables kidney transplantation in countries with unacceptably long deceaseddonor waiting lists. | Christina Melexopoulou Smaragdi Marinaki George Liapis Chrysanthi Skalioti Maria Gavalaki George Zavos John N Boletis | 2015 | World Journal of Transplantation2015，5，4： | 2 |
| 5 | Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis显示文摘 | Boletis JN Ioannidis JP Boki KA | | 0，，： | 1 |
| 6 | 查看详情显示文摘 | Papassavas AC Iniotaki-Theodoraki A Boletis J | | 0，，： | 1 |
| 7 | Primary mediastinal B- cell lymphoma显示文摘 | BOLETI E JOHNSON P W | 2007 | Hematol Oncol2007，25，： | 1 |
| 8 | Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand:an open-label trial显示文摘 | Sfikakis PP Boletis JN Lionaki S | 2005 | Arthritis Rheum2005，52，2： | 1 |
| 9 | Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatorymolecule CD40 ligand:an open-label trial显示文摘 | Sfikakis PP Boletis JN Lionaki S | 2005 | Arthritis Rheum2005，52，2： | 1 |
| 10 | Rituximab anti-Bcell therapy in systemic lupus erythematosus:pointing to the future显示文摘 | Sfikakis PP Boletis JN Tsokos GC | 2005 | Curr Opin Rheumatol2005，17，： | 1 |
| 11 | Lupus nephritis:Treatment with mycophenolate mofetil显示文摘 | Kapitsinou PP Boletis JN Skopouli FN | 2004 | Rheumatology2004，3，43： | 1 |
| 12 | The incidence of aymptomatic thromboembolism in patients receiving adjuvant-based chemotherapy for early stage breast cancer显示文摘 | i] Nolan L Darby A Boleti K | 2011 | Breast2011，20，2： | 1 |
| 13 | A limited number of HLA epitopes are recognized from HLA class Ⅰ-specific antibodies detected in the serum of sensitized patients显示文摘 | Iniotaki-Theodoraki A Boletis J | 2000 | Hum Immunol2000，61，7： | 1 |
| 14 | Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis显示文摘 | P.P. Sfikakis V.L. Souliotis K.G. Fragiadaki H.M. Moutsopoulos J.N. Boletis A.N. Theofilopoulos | 2006 | Clinical Immunology2006，，1： | 1 |
| 15 | EULAR recommendations for the management of systemic lupus erythematosus显示文摘 | Bertsias G Ioannidis J P Boletis J | 2008 | Ann Rheum Dis2008，67，2： | 1 |
| 16 | Antibody engineering: Comparison of bacterial,yeast,insect and mammalian expression system显示文摘 | Verma R Boleti E George AJT | 1998 | Immunol Methods1998，216，12： | 1 |
| 17 | Primary mediastinal B-cell lymphoma 显示文摘 | Boleti E Johnson PW | 2007 | Hematol Oncol2007，25，4： | 1 |
| 18 | Molecular identification of the equilibrative NBMPR-sensitive(es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive(ei) transport activity in human erythroleukemia ( K562 ) cells 显示文摘 | Boleti H Coe IR Baldwin SA | 1997 | Neuropharmacol1997，36，9： | 1 |
| 19 | Antibody engineering: Comparison of bacterial,yeast, insect and mammalian expression systems 显示文摘 | Verma R Boleti E George A J T | 1998 | Journal of Immunol Methods1998，216，12： | 1 |
| 20 | Remission of proliferative lupus nephritis followingB cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an openlabel trial显示文摘 | Sfikakis PP Boletis JN L ionaki S | 2005 | Arthritis Rheum2005，52，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员